KPRX · Kiora Pharmaceuticals Inc · Documents

$1.33 -0.02 (-1.48%) At close · Nov 12

Market Cap

$5.88M

4.42M

Volume · Nov 12 20.64K Avg daily vol (3M) 30.08K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $0 10-K filed Mar 25, 2026 Quarterly report New FY2026 Q3 Revenue $1M 10-Q filed Nov 12, 2026 Latest results New Financial results 8-K filed Nov 12, 2026

2026

Nov 12

Current report 8-K

Financial results AI summary on its way

Nov 12

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Quarterly report for FY2026 Q3 AI summary on its way

Revenue $1M Net loss $1.75M Diluted EPS -$0.28

Oct 29

Current report 8-K Events of Oct 23

Entered into a material agreement, Regulation FD disclosure

Kiora Pharmaceuticals entered an exclusive Senju license for KIO-401 in ophthalmology, effective October 5, 2026. Payments include $3.5 million upfront, a technology-transfer payment, up to $168.5 million in milestones and single-digit royalties.

Read from the first part of this long document

Sep 8

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure AI summary on its way

Aug 19

Current report 8-K

Entered into a material agreement, Regulation FD disclosure AI summary on its way

Aug 7

Current report 8-K

Financial results AI summary on its way

Aug 7

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way

Net loss $2.08M Diluted EPS -$0.34

Jun 18

Current report 8-K

Regulation FD disclosure AI summary on its way

Jun 11

Current report 8-K Events of Jun 10

Director or officer change, or executive pay, Shareholder vote results AI summary on its way

May 18

Registration statement S-3

Registration statement AI summary on its way

May 8

Current report 8-K

Financial results AI summary on its way

May 8

Quarterly report 10-Q FY2026 Q1, ended Mar 31

Quarterly report for FY2026 Q1 AI summary on its way

Net loss $2.42M Diluted EPS -$0.58

May 1

Annual report to holders ARS

Annual report to holders AI summary on its way

Apr 30

Proxy statement DEF 14A

Proxy statement AI summary on its way

Apr 7

Current report 8-K Events of Apr 3

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure AI summary on its way

Apr 2

Current report 8-K Events of Apr 1

Director or officer change, or executive pay, Regulation FD disclosure AI summary on its way

Mar 25

Current report 8-K

Financial results AI summary on its way

Mar 25

Annual report 10-K FY2025, ended Dec 31

Annual report for FY2025 AI summary on its way

Revenue $0 Net loss $10.84M Diluted EPS -$2.64

2025

Nov 7

Current report 8-K

Financial results

Nov 7

Quarterly report 10-Q FY2025 Q3, ended Sep 30

Quarterly report for FY2025 Q3

Revenue $0 Net income $26.81K Diluted EPS $0.01

Sep 15

Registration statement S-3

Registration statement

Aug 13

Current report 8-K

Regulation FD disclosure

Aug 8

Current report 8-K

Financial results

Aug 8

Quarterly report 10-Q FY2025 Q2, ended Jun 30

Quarterly report for FY2025 Q2

Revenue $0 Net loss $2.15M Diluted EPS -$0.54

Jun 4

Current report 8-K

Shareholder vote results

Jun 3

Current report 8-K Events of May 30

Entered into a material agreement, Regulation FD disclosure

May 9

Current report 8-K

Financial results

May 9

Quarterly report 10-Q FY2025 Q1, ended Mar 31

Quarterly report for FY2025 Q1

Revenue $0 Net loss $2.19M Diluted EPS -$0.52

Apr 30

Proxy statement DEF 14A

Proxy statement

Mar 25

Current report 8-K

Financial results

Mar 25

Annual report 10-K FY2024, ended Dec 31

Annual report for FY2024

Revenue $16.02M Net income $3.59M Diluted EPS $0.87

Jan 15

Current report 8-K Events of Jan 10

Director or officer change, or executive pay

2024

Nov 8

Current report 8-K

Financial results

Nov 8

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Revenue $0 Net loss $3.41M Diluted EPS -$0.81

Oct 29

Current report 8-K

Regulation FD disclosure

Aug 9

Current report 8-K

Financial results

Aug 9

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $20K Net loss $2.22M Diluted EPS -$0.53

Jul 30

Current report 8-K

Other events

Jul 1

Current report 8-K Events of Jun 28

Director or officer change, or executive pay, Regulation FD disclosure, Other events

Jun 7

Current report 8-K Events of Jun 6

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Other events

May 10

Current report 8-K

Financial results

May 10

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $16M Net income $13.45M Diluted EPS $0.38

May 3

Current report 8-K Events of May 1

Charter or bylaw amendment, or fiscal year change, Shareholder vote results

Mar 25

Proxy statement DEF 14A Meeting May 1, 2024

Proxy statement

Mar 25

Current report 8-K

Financial results

Mar 25

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Net loss $12.51M Diluted EPS -$2.69

Mar 15

Proxy statement PRE 14A Meeting May 1, 2024

Proxy statement

Feb 28

Registration statement S-3

Registration statement

Feb 12

Current report 8-K

Regulation FD disclosure

Feb 1

Current report 8-K Events of Jan 31

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure

Showing 1–50 of 155 documents

Key facts CIK 1372514 CUSIP 49721T507 13F (30d) 11 filings 9 filers Visit website